



## **Fidia Presents New Data on Hymovis<sup>®</sup>, a Breakthrough in Viscoelastic Technology, at the American Orthopaedic Society for Sports Medicine 2016 Annual Meeting**

*Hymovis<sup>®</sup> is a highly viscoelastic hydrogel (HYADD<sup>®</sup>4) engineered using a proprietary process that increases lubrication and shock absorption properties; new data demonstrating long-term benefits of Hymovis<sup>®</sup> in alleviating osteoarthritis knee pain and stiffness and improving physical function and quality of life will be presented.*

**PARSIPPANY, N.J., July 5, 2016** – Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronic acid (HA)-based products, and its wholly owned subsidiary, Fidia Pharma USA Inc., will feature Hymovis<sup>®</sup> (high molecular weight viscoelastic hyaluronan), which is now commercially available in the U.S., at the Annual Meeting of the American Orthopaedic Society for Sports Medicine (AOSSM) in Colorado Springs, Colorado, July 7-10, 2016.

Hymovis<sup>®</sup> is a highly viscoelastic hydrogel (HYADD<sup>®</sup>4) bioengineered using a proprietary process that increases lubrication and shock absorption properties and results in a natural hyaluronan similar to the hyaluronan found in the synovial fluid present in human joints. The formulation allows the unique molecule to recover its original structure, even after repetitive mechanical stress. Due to reversible hydrophobic interactions, the non-crosslinked Hymovis<sup>®</sup> has increased elasticity, viscosity and residence time in the joint.\*

Hymovis<sup>®</sup> will be featured at an industry symposium sponsored by Fidia Pharma USA on Thursday, July 7, from 12:30 – 2 p.m., at the Broadmoor in Colorado Springs. Distinguished faculty will present in the resort's Colorado Hall A, including Dr. Clarence L. Shields, M.D., an orthopaedic surgeon specializing in Sports Medicine at Kerlan-Jobe Orthopaedic Clinic in Los Angeles; Dr. Lawrence Bonassar, Ph.D. Professor at the Meinig School of Biomedical Engineering at Cornell University; and Dr. Francesco Benazzo M.D., Chairman of the Department of Orthopaedics and Traumatology at the University of Pavia in Italy.

Notably, the results of a prospective, multi-center study to evaluate the long-term efficacy and safety of Hymovis<sup>®</sup> will be presented for the first time in the U.S. by Dr. Francesco Benazzo, the lead investigator.

“Our study clearly shows the unique viscoelastic characteristics of Hymovis<sup>®</sup> translates into long-term benefits for patients with knee pain due to osteoarthritis by alleviating the knee pain and stiffness and improving physical function and quality of life,” states Dr. Benazzo.

Dr. Clarence L. Shields adds that “Hymovis<sup>®</sup> represents an important new treatment option for orthopedic surgeon/sports medicine physicians and their patients, particularly those who are active, high-demand patients with OA knee pain.”

Further information can be found at the Fidia booth (Booth #219) in the Exhibit Hall or at [www.hymovis.com](http://www.hymovis.com).

### **About Fidia Pharma USA Inc.**

Fidia Pharma USA Inc is a wholly-owned subsidiary of Italian pharmaceutical manufacturer Fidia Farmaceutici S.p.A., an established leader in the hyaluronic acid market segment.

Fidia Pharma USA Inc. is focused on expanding Fidias position in the U.S. and Canadian market, while upholding the companys mission to provide consumers with innovative products that offer quality, safety and performance. Fidias Pharma USA Inc. is headquartered in Parsippany, NJ. For more information, please visit [www.fidiapharma.us](http://www.fidiapharma.us).

### **About Fidias Farmaceutici S.p.A.**

Fidias Farmaceutici S.p.A. is an Italian pharmaceutical company founded in 1946. It is a leader in research and marketing hyaluronic acid-based products, with several applications in the biomedical field, such as rheumatology, orthopaedics, surgery, wound care, tissue repair and dermo-aesthetics. Fidias Farmaceutici is part of the P&R Holding group. The company is located in Italy, with R&D facilities in Abano Terme (Padua) and Noto (Sicily). Fidias has more than 700 employees, and its revenue exceeds €250 million euros. Fidias Farmaceutici S.p.A.s products are marketed in more than 100 countries, through wholly owned subsidiaries and a comprehensive network of international partnerships and distributors. Thanks to its investment in research, it has created a legacy of products with more than 600 patents to its name. For more information, please visit [www.fidiapharma.com](http://www.fidiapharma.com).

### **For more information, contact:**

Fidias Pharma USA Inc.  
Morris Corporate Center 1  
Building C, 1st floor  
300 Interpace Parkway  
Parsippany, NJ 07054  
1-973-507-5120  
[ckong@fidiapharma.us](mailto:ckong@fidiapharma.us)

### **Indication**

Hymovis<sup>®</sup> is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy or simple analgesics (e.g., acetaminophen).

### **Important Safety Information**

Hymovis<sup>®</sup> is contraindicated in patients with known hypersensitivity (allergy) to hyaluronate preparations or gram positive bacterial proteins. Do not administer Hymovis<sup>®</sup> to patients with infections or skin diseases in the area of the injection site or joint.

The safety and effectiveness of the use of Hymovis<sup>®</sup> has not been tested in pregnant women, nursing mothers or children. The safety and effectiveness of the use of Hymovis<sup>®</sup> in joints other than the knee, or for use concomitantly with other intra-articular (IA) injections has not been established. The effectiveness of repeat treatment cycles of Hymovis<sup>®</sup> has not been established. Arthralgia, transient pain or swelling may occur after the IA injection. The incidence of arthralgia in the clinical study for Hymovis<sup>®</sup> was equivalent to the control group. No serious adverse reactions or pseudoseptic reactions were reported. Transient increases in inflammation following any IA hyaluronan injection have been reported in some patients with inflammatory joint conditions.

\*Preclinical studies may not be indicative of human clinical outcomes.

Rx Only

###